NEWS
Aimei Vaccine's heavy single product is about to enter the harvest period, and its growth momentum is unstoppable
As a rare full industry chain vaccine group in China, Aimei Vaccine (06660) announced that its heavy single product is about to enter the harvest period. Last Thursday, the stock price rose rapidly, soaring by 4.99% for the entire day, closing at HK$49.4, with a total market value of HK$59.8 billion. Investors should closely monitor the recent trend of the stock price and make early deployments.
The group recently announced a continuous increase in innovation investment, with research and development expenditures in the first half of the year reaching approximately RMB 399 million, an increase of RMB 205 million compared to the first half of 2022, reflecting a 105.4% increase. Under continuous strong investment, the group's pipeline continues to make breakthroughs, reflecting the continuous strengthening of the group's core competitiveness. With the support of favorable policies, potential value is continuously being released.
Earlier, the group initiated the Phase III randomized, double-blind, same-type vaccine controlled clinical trial of the 23-valent pneumococcal polysaccharide vaccine in the southern county disease control center in Sichuan Province. This study will be conducted in two locations in Sichuan Province and one location in Shandong Province, with plans to enroll 1,920 healthy subjects aged 2 years and older. The Phase I clinical trial of the 23-valent pneumococcal polysaccharide vaccine was initiated in December 2021 at the disease control center in the southern county of Sichuan Province. As of now, safety and immunogenicity analysis results show that this product is safe and exhibits good immunogenicity.
With the improvement of China's economic strength, the biotechnology industry, including the vaccine industry, has been positioned as a national strategic emerging industry to be encouraged and supported. Relevant industrial policies such as "Made in China 2025", "13th Five-Year Plan for the Development of the Biotechnology Industry", and "Guidelines for the Development of the Pharmaceutical Industry" encourage the development of multi-valent vaccines, genetic engineering vaccines, viral vector vaccines, nucleic acid vaccines, and other new types of vaccines in the vaccine industry, achieving the upgrade and replacement of some immunization program vaccines. Strong support from national industrial policies is conducive to the development of the Chinese vaccine industry.
Aimei Vaccine is a rare medical stock in the Hong Kong stock market. Currently, it has eight commercialized vaccine products targeting six disease areas. The group's Phase III clinical heavy vaccines, including the 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), and freeze-dried human rabies vaccine (serum-free Vero cells), have entered the final stage of clinical trials, with corresponding production capacities ready, and the products are entering the market launch sprint stage. Among them, the designed production capacity of the pneumonia vaccine production workshop reaches 45 million doses, while the serum-free Vero cell rabies vaccine and human diploid cell rabies vaccine production workshops have a designed production capacity of 50 million doses each. The meningococcal vaccine production workshop has a designed production capacity of 35 million doses, with mature commercial realization paths.
During the period, Aimei Vaccine received favor from the capital market on several occasions. In February 2023, the group was included in the Hang Seng Composite Index. In March, it was included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. On March 8th, the group announced a proposal to issue non-listed RMB ordinary shares to further enhance the group's competitive strength and promote the healthy development of its business.
In addition, Aimei Vaccine announced last week that the group has received approval from the China Securities Regulatory Commission for the issuance of shares to specific entities ("Approval for Aimei Vaccine Co., Ltd. to Issue Shares to Specific Objects" [CSRC Permit [2023] No. 1816]). The China Securities Regulatory Commission has approved the issuance of these non-listed RMB ordinary shares. This issuance of domestic shares by Aimei Vaccine is non-negotiable and is aimed at raising RMB funds in the domestic primary market. The highly probable exit route for these funds is through an A-share listing, and it cannot be ruled out that there is a plan for an A-share listing, increasing the group's visibility in the capital market. The current environment in the Hong Kong stock market has created a mismatch between the group's high growth and low valuation; however, the discovery of value will not be absent, and this historic opportunity for building positions should not be missed.
The group recently announced a continuous increase in innovation investment, with research and development expenditures in the first half of the year reaching approximately RMB 399 million, an increase of RMB 205 million compared to the first half of 2022, reflecting a 105.4% increase. Under continuous strong investment, the group's pipeline continues to make breakthroughs, reflecting the continuous strengthening of the group's core competitiveness. With the support of favorable policies, potential value is continuously being released.
Earlier, the group initiated the Phase III randomized, double-blind, same-type vaccine controlled clinical trial of the 23-valent pneumococcal polysaccharide vaccine in the southern county disease control center in Sichuan Province. This study will be conducted in two locations in Sichuan Province and one location in Shandong Province, with plans to enroll 1,920 healthy subjects aged 2 years and older. The Phase I clinical trial of the 23-valent pneumococcal polysaccharide vaccine was initiated in December 2021 at the disease control center in the southern county of Sichuan Province. As of now, safety and immunogenicity analysis results show that this product is safe and exhibits good immunogenicity.
With the improvement of China's economic strength, the biotechnology industry, including the vaccine industry, has been positioned as a national strategic emerging industry to be encouraged and supported. Relevant industrial policies such as "Made in China 2025", "13th Five-Year Plan for the Development of the Biotechnology Industry", and "Guidelines for the Development of the Pharmaceutical Industry" encourage the development of multi-valent vaccines, genetic engineering vaccines, viral vector vaccines, nucleic acid vaccines, and other new types of vaccines in the vaccine industry, achieving the upgrade and replacement of some immunization program vaccines. Strong support from national industrial policies is conducive to the development of the Chinese vaccine industry.
Aimei Vaccine is a rare medical stock in the Hong Kong stock market. Currently, it has eight commercialized vaccine products targeting six disease areas. The group's Phase III clinical heavy vaccines, including the 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), and freeze-dried human rabies vaccine (serum-free Vero cells), have entered the final stage of clinical trials, with corresponding production capacities ready, and the products are entering the market launch sprint stage. Among them, the designed production capacity of the pneumonia vaccine production workshop reaches 45 million doses, while the serum-free Vero cell rabies vaccine and human diploid cell rabies vaccine production workshops have a designed production capacity of 50 million doses each. The meningococcal vaccine production workshop has a designed production capacity of 35 million doses, with mature commercial realization paths.
During the period, Aimei Vaccine received favor from the capital market on several occasions. In February 2023, the group was included in the Hang Seng Composite Index. In March, it was included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. On March 8th, the group announced a proposal to issue non-listed RMB ordinary shares to further enhance the group's competitive strength and promote the healthy development of its business.
In addition, Aimei Vaccine announced last week that the group has received approval from the China Securities Regulatory Commission for the issuance of shares to specific entities ("Approval for Aimei Vaccine Co., Ltd. to Issue Shares to Specific Objects" [CSRC Permit [2023] No. 1816]). The China Securities Regulatory Commission has approved the issuance of these non-listed RMB ordinary shares. This issuance of domestic shares by Aimei Vaccine is non-negotiable and is aimed at raising RMB funds in the domestic primary market. The highly probable exit route for these funds is through an A-share listing, and it cannot be ruled out that there is a plan for an A-share listing, increasing the group's visibility in the capital market. The current environment in the Hong Kong stock market has created a mismatch between the group's high growth and low valuation; however, the discovery of value will not be absent, and this historic opportunity for building positions should not be missed.
